3 days ago 4

BridgeBio price target raised to $42 from $37 at BMO Capital

BridgeBio price target raised to $42 from $37 at BMO Capital

TipRanks

Thu, Jun 5, 2025, 5:50 AM 1 min read

In This Article:

BMO Capital raised the firm’s price target on BridgeBio (BBIO) to $42 from $37 and keeps a Market Perform rating on the shares. The firm anticipates Attruby’s U.S. sales in Q2 to be $77M-$89M, reflecting 110%-145% sequential growth and 20%-40% revenues above consensus, helping to drive 5%-15% upside in BridgeBio shares, the analyst tells investors in a research note.

Confident Investing Starts Here:

Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on BBIO:

Disclaimer & Disclosure Report an Issue

Terms and Privacy Policy

Privacy Dashboard

Recommended Stories

Read Entire Article

From Twitter

Comments